Literature DB >> 21531946

Impact of molecular prognostic factors in cytogenetically normal acute myeloid leukemia at diagnosis and relapse.

Alison Walker, Guido Marcucci.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21531946      PMCID： PMC3084908          DOI： 10.3324/haematol.2011.042739

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  33 in total

Review 1.  Nucleophosmin and cancer.

Authors:  Silvia Grisendi; Cristina Mecucci; Brunangelo Falini; Pier Paolo Pandolfi
Journal:  Nat Rev Cancer       Date:  2006-07       Impact factor: 60.716

2.  Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.

Authors:  Brunangelo Falini; Cristina Mecucci; Enrico Tiacci; Myriam Alcalay; Roberto Rosati; Laura Pasqualucci; Roberta La Starza; Daniela Diverio; Emanuela Colombo; Antonella Santucci; Barbara Bigerna; Roberta Pacini; Alessandra Pucciarini; Arcangelo Liso; Marco Vignetti; Paola Fazi; Natalia Meani; Valentina Pettirossi; Giuseppe Saglio; Franco Mandelli; Francesco Lo-Coco; Pier-Giuseppe Pelicci; Massimo F Martelli
Journal:  N Engl J Med       Date:  2005-01-20       Impact factor: 91.245

3.  Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis.

Authors:  Christian Thiede; Christine Steudel; Brigitte Mohr; Markus Schaich; Ulrike Schäkel; Uwe Platzbecker; Martin Wermke; Martin Bornhäuser; Markus Ritter; Andreas Neubauer; Gerhard Ehninger; Thomas Illmer
Journal:  Blood       Date:  2002-06-15       Impact factor: 22.113

4.  Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations.

Authors:  Konstanze Döhner; Richard F Schlenk; Marianne Habdank; Claudia Scholl; Frank G Rücker; Andrea Corbacioglu; Lars Bullinger; Stefan Fröhling; Hartmut Döhner
Journal:  Blood       Date:  2005-07-28       Impact factor: 22.113

5.  High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study.

Authors:  Guido Marcucci; Kati Maharry; Susan P Whitman; Tamara Vukosavljevic; Peter Paschka; Christian Langer; Krzysztof Mrózek; Claudia D Baldus; Andrew J Carroll; Bayard L Powell; Jonathan E Kolitz; Richard A Larson; Clara D Bloomfield
Journal:  J Clin Oncol       Date:  2007-06-18       Impact factor: 44.544

6.  MicroRNA expression in cytogenetically normal acute myeloid leukemia.

Authors:  Guido Marcucci; Michael D Radmacher; Kati Maharry; Krzysztof Mrózek; Amy S Ruppert; Peter Paschka; Tamara Vukosavljevic; Susan P Whitman; Claudia D Baldus; Christian Langer; Chang-Gong Liu; Andrew J Carroll; Bayard L Powell; Ramiro Garzon; Carlo M Croce; Jonathan E Kolitz; Michael A Caligiuri; Richard A Larson; Clara D Bloomfield
Journal:  N Engl J Med       Date:  2008-05-01       Impact factor: 91.245

7.  Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.

Authors:  Richard F Schlenk; Konstanze Döhner; Jürgen Krauter; Stefan Fröhling; Andrea Corbacioglu; Lars Bullinger; Marianne Habdank; Daniela Späth; Michael Morgan; Axel Benner; Brigitte Schlegelberger; Gerhard Heil; Arnold Ganser; Hartmut Döhner
Journal:  N Engl J Med       Date:  2008-05-01       Impact factor: 91.245

8.  Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin.

Authors:  Ramiro Garzon; Michela Garofalo; Maria Paola Martelli; Roger Briesewitz; Lisheng Wang; Cecilia Fernandez-Cymering; Stefano Volinia; Chang-Gong Liu; Susanne Schnittger; Torsten Haferlach; Arcangelo Liso; Daniela Diverio; Marco Mancini; Giovanna Meloni; Robin Foa; Massimo F Martelli; Cristina Mecucci; Carlo M Croce; Brunangelo Falini
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-28       Impact factor: 11.205

9.  Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461).

Authors:  John C Byrd; Krzysztof Mrózek; Richard K Dodge; Andrew J Carroll; Colin G Edwards; Diane C Arthur; Mark J Pettenati; Shivanand R Patil; Kathleen W Rao; Michael S Watson; Prasad R K Koduru; Joseph O Moore; Richard M Stone; Robert J Mayer; Eric J Feldman; Frederick R Davey; Charles A Schiffer; Richard A Larson; Clara D Bloomfield
Journal:  Blood       Date:  2002-08-01       Impact factor: 22.113

10.  Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study.

Authors:  Susan P Whitman; Amy S Ruppert; Guido Marcucci; Krzysztof Mrózek; Peter Paschka; Christian Langer; Claudia D Baldus; Jing Wen; Tamara Vukosavljevic; Bayard L Powell; Andrew J Carroll; Jonathan E Kolitz; Richard A Larson; Michael A Caligiuri; Clara D Bloomfield
Journal:  Blood       Date:  2007-03-06       Impact factor: 22.113
View more
  7 in total

1.  Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia.

Authors:  Aziz Nazha; Jorge Cortes; Stefan Faderl; Sherry Pierce; Naval Daver; Tapan Kadia; Gautam Borthakur; Raja Luthra; Hagop Kantarjian; Farhad Ravandi
Journal:  Haematologica       Date:  2012-04-24       Impact factor: 9.941

2.  Primetime for chemotherapy in acute myeloid leukemia.

Authors:  Jan Cools
Journal:  Haematologica       Date:  2012-12       Impact factor: 9.941

3.  The N676D and G697R mutations in the kinase domain of FLT3 confer resistance to the inhibitor AC220.

Authors:  Daphnie Pauwels; Bram Sweron; Jan Cools
Journal:  Haematologica       Date:  2012-08-08       Impact factor: 9.941

4.  Influence of molecular subgroups on outcome of acute myeloid leukemia with normal karyotype in 141 patients undergoing salvage allogeneic stem cell transplantation in primary induction failure or beyond first relapse.

Authors:  Tim Pfeiffer; Michael Schleuning; Jiri Mayer; Karl-Heinz Haude; Johanna Tischer; Stefanie Buchholz; Donald Bunjes; Gesine Bug; Ernst Holler; Ralf G Meyer; Hildegard Greinix; Christof Scheid; Maximilian Christopeit; Susanne Schnittger; Jan Braess; Günter Schlimok; Karsten Spiekermann; Arnold Ganser; Hans-Jochem Kolb; Christoph Schmid
Journal:  Haematologica       Date:  2012-09-14       Impact factor: 9.941

5.  Transcriptome sequencing reveals CHD1 as a novel fusion partner of RUNX1 in acute myeloid leukemia with t(5;21)(q21;q22).

Authors:  Hong Yao; Jinlan Pan; Chunxiao Wu; Hongjie Shen; Jundan Xie; Qinrong Wang; Lijun Wen; Qian Wang; Liang Ma; Lili Wu; Nana Ping; Yun Zhao; Aining Sun; Suning Chen
Journal:  Mol Cancer       Date:  2015-04-11       Impact factor: 27.401

6.  Overexpression of MN1 confers resistance to chemotherapy, accelerates leukemia onset, and suppresses p53 and Bim induction.

Authors:  Timothy S Pardee
Journal:  PLoS One       Date:  2012-08-14       Impact factor: 3.240

7.  FISH+CD34+CD38- cells detected in newly diagnosed acute myeloid leukemia patients can predict the clinical outcome.

Authors:  Libing Wang; Lei Gao; Sheng Xu; Shenglan Gong; Li Chen; Shuqing Lü; Jie Chen; Huiying Qiu; Xiaoqian Xu; Xiong Ni; Xianmin Song; Weiping Zhang; Jianmin Yang; Min Liu; Xiaoxia Hu; Jianmin Wang
Journal:  J Hematol Oncol       Date:  2013-11-07       Impact factor: 17.388
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.